Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Ferber

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Journal of Clinical Pharmacology|July 6, 2026
How to Replace the TQT Study-The Use of Concentration-QTc Modeling to Exclude a Small Effect of a Novel Drug on QT Interval: Historical Perspective and ImplementationBorje Darpo, Georg Ferber, Seth C Hopkins, et al.
Journal of Clinical Pharmacology|June 9, 2016
Can Bias Evaluation Provide Protection Against False-Negative Results in QT Studies Without a Positive Control Using Exposure-Response Analysis?Georg Ferber, Meijian Zhou, Corina Dota, et al.
British Journal of Clinical Pharmacology|July 11, 2012
Insulin at normal physiological levels does not prolong QT(c) interval in thorough QT studies performed in healthy volunteersJorg Taubel, Ulrike Lorch, Georg Ferber, et al.
Clinical Pharmacology in Drug Development|March 1, 2018
Confirmation of the Cardiac Safety of PGF<sub>2α</sub> Receptor Antagonist OBE022 in a First-in-Human Study in Healthy Subjects, Using Intensive ECG AssessmentsJörg Täubel, Ulrike Lorch, Simon Coates, et al.
Neurology and Therapy|February 22, 2023
Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic DoseBorje Darpo, Michal Geva, Georg Ferber, et al.
Journal of Pharmacological and Toxicological Methods|May 22, 2013
Preclinical QT safety assessment: cross-species comparisons and human translation from an industry consortiumHenry Holzgrefe, Georg Ferber, Pascal Champeroux, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 1, 2019
Cardiac risk assessment based on early Phase I data and PK-QTc analysis is concordant with the outcome of thorough QTc trials: an assessment based on eleven drug candidatesPuneet Gaitonde, Yeamin Huh, Borje Darpo, et al.
British Journal of Clinical Pharmacology|March 24, 2012
Comparison of the effects of levofloxacin on QT/QTc interval assessed in both healthy Japanese and Caucasian subjects (pagesAtsushi Sugiyama, Yuji Nakamura, Satomi Nishimura, et al.
BMC Neurology|April 3, 2012
How to improve walking, balance and social participation following stroke: a comparison of the long term effects of two walking aids--canes and an orthosis TheraTogs--on the recovery of gait following acute stroke. A study protocol for a multi-centre, single blind, randomised control trialClare Maguire, Judith M Sieben, Florian Erzer, et al.
Scientific Reports|March 19, 2021
Confirmation of the cardiac safety of nolasiban in a randomised cohort of healthy female volunteersJörg Täubel, Ulrike Lorch, Christopher S Spencer, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Journal of Clinical Pharmacology|July 6, 2026
How to Replace the TQT Study-The Use of Concentration-QTc Modeling to Exclude a Small Effect of a Novel Drug on QT Interval: Historical Perspective and ImplementationBorje Darpo, Georg Ferber, Seth C Hopkins, et al.
Journal of Clinical Pharmacology|June 9, 2016
Can Bias Evaluation Provide Protection Against False-Negative Results in QT Studies Without a Positive Control Using Exposure-Response Analysis?Georg Ferber, Meijian Zhou, Corina Dota, et al.
British Journal of Clinical Pharmacology|July 11, 2012
Insulin at normal physiological levels does not prolong QT(c) interval in thorough QT studies performed in healthy volunteersJorg Taubel, Ulrike Lorch, Georg Ferber, et al.
Clinical Pharmacology in Drug Development|March 1, 2018
Confirmation of the Cardiac Safety of PGF<sub>2α</sub> Receptor Antagonist OBE022 in a First-in-Human Study in Healthy Subjects, Using Intensive ECG AssessmentsJörg Täubel, Ulrike Lorch, Simon Coates, et al.
Neurology and Therapy|February 22, 2023
Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic DoseBorje Darpo, Michal Geva, Georg Ferber, et al.
Journal of Pharmacological and Toxicological Methods|May 22, 2013
Preclinical QT safety assessment: cross-species comparisons and human translation from an industry consortiumHenry Holzgrefe, Georg Ferber, Pascal Champeroux, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 1, 2019
Cardiac risk assessment based on early Phase I data and PK-QTc analysis is concordant with the outcome of thorough QTc trials: an assessment based on eleven drug candidatesPuneet Gaitonde, Yeamin Huh, Borje Darpo, et al.
British Journal of Clinical Pharmacology|March 24, 2012
Comparison of the effects of levofloxacin on QT/QTc interval assessed in both healthy Japanese and Caucasian subjects (pagesAtsushi Sugiyama, Yuji Nakamura, Satomi Nishimura, et al.
BMC Neurology|April 3, 2012
How to improve walking, balance and social participation following stroke: a comparison of the long term effects of two walking aids--canes and an orthosis TheraTogs--on the recovery of gait following acute stroke. A study protocol for a multi-centre, single blind, randomised control trialClare Maguire, Judith M Sieben, Florian Erzer, et al.
Scientific Reports|March 19, 2021
Confirmation of the cardiac safety of nolasiban in a randomised cohort of healthy female volunteersJörg Täubel, Ulrike Lorch, Christopher S Spencer, et al.
Pageof 6